Stock Traders Buy High Volume of Put Options on Aerie Pharmaceuticals (AERI)

Aerie Pharmaceuticals Inc (NASDAQ:AERI) was the recipient of some unusual options trading on Wednesday. Investors purchased 1,088 put options on the stock. This is an increase of 1,022% compared to the average daily volume of 97 put options.

Shares of Aerie Pharmaceuticals (AERI) opened at $52.55 on Friday. Aerie Pharmaceuticals has a twelve month low of $38.14 and a twelve month high of $66.60. The firm has a market capitalization of $1,930.00, a PE ratio of -15.69 and a beta of 0.87. The company has a quick ratio of 15.24, a current ratio of 15.24 and a debt-to-equity ratio of 0.78.

Aerie Pharmaceuticals (NASDAQ:AERI) last announced its quarterly earnings data on Wednesday, November 8th. The company reported ($0.89) earnings per share for the quarter. analysts forecast that Aerie Pharmaceuticals will post -3.97 earnings per share for the current year.

Institutional investors and hedge funds have recently made changes to their positions in the stock. Ameritas Investment Partners Inc. increased its holdings in Aerie Pharmaceuticals by 11.5% in the 2nd quarter. Ameritas Investment Partners Inc. now owns 2,665 shares of the company’s stock worth $140,000 after acquiring an additional 275 shares during the last quarter. Public Employees Retirement Association of Colorado purchased a new stake in Aerie Pharmaceuticals in the 4th quarter worth about $176,000. Quantbot Technologies LP grew its holdings in Aerie Pharmaceuticals by 792.5% during the 3rd quarter. Quantbot Technologies LP now owns 2,981 shares of the company’s stock valued at $144,000 after buying an additional 2,647 shares in the last quarter. Amalgamated Bank purchased a new position in Aerie Pharmaceuticals during the 2nd quarter valued at about $204,000. Finally, Great West Life Assurance Co. Can grew its holdings in Aerie Pharmaceuticals by 65.0% during the 3rd quarter. Great West Life Assurance Co. Can now owns 4,160 shares of the company’s stock valued at $204,000 after buying an additional 1,639 shares in the last quarter. 97.89% of the stock is owned by institutional investors.

Several brokerages have recently issued reports on AERI. Zacks Investment Research raised Aerie Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Friday. Canaccord Genuity reaffirmed a “positive” rating and set a $73.00 target price (up from $65.00) on shares of Aerie Pharmaceuticals in a research report on Monday, October 16th. Needham & Company LLC reaffirmed a “buy” rating and set a $76.00 target price (up from $65.00) on shares of Aerie Pharmaceuticals in a research report on Monday, October 16th. Mizuho reaffirmed a “buy” rating and set a $70.00 target price on shares of Aerie Pharmaceuticals in a research report on Monday, October 16th. Finally, Guggenheim began coverage on Aerie Pharmaceuticals in a research report on Monday, October 23rd. They set a “buy” rating and a $80.00 target price for the company. Four equities research analysts have rated the stock with a hold rating and thirteen have given a buy rating to the company. Aerie Pharmaceuticals presently has an average rating of “Buy” and a consensus price target of $73.27.

ILLEGAL ACTIVITY NOTICE: “Stock Traders Buy High Volume of Put Options on Aerie Pharmaceuticals (AERI)” was published by Transcript Daily and is owned by of Transcript Daily. If you are viewing this news story on another site, it was illegally copied and republished in violation of United States & international trademark & copyright laws. The original version of this news story can be viewed at https://transcriptdaily.com/2018/02/10/stock-traders-buy-high-volume-of-put-options-on-aerie-pharmaceuticals-aeri.html.

Aerie Pharmaceuticals Company Profile

Aerie Pharmaceuticals, Inc is a clinical-stage pharmaceutical company. The Company is engaged in the discovery, development and commercialization of therapies for the treatment of patients with glaucoma and other diseases of the eye. The Company’s product candidates include Rhopressa (netarsudil ophthalmic solution) 0.02% (Rhopressa), and Roclatan (netarsudil/latanoprost ophthalmic solution) 0.02%/0.005% (Roclatan).

Receive News & Ratings for Aerie Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aerie Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply